Ocugen, Inc. (OCGN) PT Lowered to $4.50 at Chardan Capital Markets
- Stocks close with gains, led by Dow as investors look for rate insight
- Piper Sandler: Stock rally likely to continue on rising recession risks
- Robinhood (HOOD) rises after saying it plans to launch a credit card for US consumers
- Short sellers target Reddit shares as stock slips
- RH touts 'exceptional' demand for new collections after Q4 results fall short
- Discover Financial Services (DFS) Announces CEO Resignation
- Timken (TKR) Appoints Tarak Mehta as New CEO
- Crude Inventory Increases 3.2 Million Barrels
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Many senior Amazon employees won't get cash raises this year - Fortune
Ocugen Inc. Announces Michael Shine as Senior Vice President, Commercial
June 10, 2021 7:35 AM EDTMALVERN, Pa., June 10, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that Michael Shine will be joining Ocugen as Senior Vice President, Commercial.
Michael Shine is a pharmaceutical and biotechnology executive with nearly 35 years of industry experience. Over the course of his career, Mr.... More
Ocugen to pursue a BLA path in the US for its COVID-19 vaccine candidate
June 10, 2021 7:30 AM EDTCompany intends to work with the FDA towards filing a Biologics License Application (BLA) in the USCompany to engage with Health Canada to seek authorization under Interim Order for use in Canada
MALVERN, Pa., June 10, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN) (Company), a biopharmaceutical company focused on discovering,... More